阿斯利康(AZN.US)投資500億美元擴大美國生產及研發能力
外電報道,阿斯利康(AZN.US)宣布計劃在2030年前斥500億美元擴大美國的生產及研發能力,作為應對美國關稅政策的重大投資。
阿斯利康將會在維珍尼亞州建立新廠房,並擴大馬里蘭州、麻薩諸塞州、加州、印第安納州及德州的研發及干細胞療法生產。
阿斯利康稱,今次投資將支持到2030年實現年收入800億美元的目標,當中一半的收入將來自美國。而在維珍尼亞州建廠房將會是公司最大的單一筆提升製造能力的投資,將生產實驗性減肥藥物的活性成分。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.